Emerging technologies and challenges for better and safer drugs

Area of Science:

• Pharmacology
• Toxicology
• Biotechnology

Background:

• Despite regulations, predicting human drug toxicity is imperfect, causing post-marketing adverse drug reactions.
• High failure costs drive the need for early-stage toxicity screening in drug development.
• Biotechnology advancements, including toxicogenomics, offer improved toxicity assessment capabilities.

Purpose of the Study:

• To highlight the ongoing challenges in predicting drug toxicity.
• To emphasize the importance of early toxicity detection in pharmaceutical research.
• To discuss the integration of diverse methods for comprehensive toxicity evaluation.

Main Methods:

• Review of current toxicological assessment strategies.
• Exploration of toxicogenomics as a modern screening tool.
• Integration of in silico, in vitro, and in vivo methodologies.

Main Results:

• Current toxicity prediction methods are insufficient, leading to late-stage adverse event detection.
• Toxicogenomics shows promise for enhancing preclinical and clinical toxicology.
• A multi-pronged approach combining various methods is necessary for robust toxicity prediction.

Conclusions:

• Improved drug development relies on early and accurate toxicity prediction.
• Integrating diverse toxicological methods is key to understanding mechanisms and minimizing risks.
• Further research into toxicological mechanisms is essential for safer pharmaceuticals.